Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
LifeVantage
LFVN
$82.9M
| $2.9M | ﹤0.01% |
670,271
+69,700
| +12% | +$307K |
|
|
KDNY
2052
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.89M | ﹤0.01% |
50,740
+14,360
| +39% | +$721K |
|
|
ONIT
2053
Onity Group
ONIT
$328M
| $2.89M | ﹤0.01% |
71,580
+53,675
| +300% | +$2.55M |
|
2054
Howmet Aerospace
HWM
$115B
| $2.88M | ﹤0.01% |
165,999
-1,339,599
| -89% | -$27.3M |
|
|
AAIC
2055
DELISTED
Arlington Asset Investment Corp.
AAIC
| $2.88M | ﹤0.01% |
+210,875
| New | +$3.03M |
|
2056
Friedman Industries
FRD
$331M
| $2.88M | ﹤0.01% |
507,000
+22,900
| +5% | +$133K |
|
|
AHGP
2057
DELISTED
Alliance Holdings GP
AHGP
| $2.88M | ﹤0.01% |
121,300
+36,420
| +43% | +$1M |
|
2058
Crawford & Co Class A
CRD.A
$632M
| $2.86M | ﹤0.01% |
367,900
-25,972
| -7% | -$209K |
|
|
SFE
2059
DELISTED
Safeguard Scientifics, Inc.
SFE
| $2.85M | ﹤0.01% |
239,717
+7,435
| +3% | +$87.5K |
|
|
WLH
2060
DELISTED
WILLIAM LYON HOMES
WLH
| $2.83M | ﹤0.01% |
117,100
+91,900
| +365% | +$2.05M |
|
2061
Napco Security Technologies
NSSC
$1.37B
| $2.83M | ﹤0.01% |
601,236
+112,092
| +23% | +$548K |
|
|
NGHC
2062
DELISTED
National General Holdings Corp
NGHC
| $2.83M | ﹤0.01% |
+133,900
| New | +$2.95M |
|
|
VRN
2063
DELISTED
Veren
VRN
| $2.82M | ﹤0.01% |
+368,800
| New | +$3.45M |
|
2064
Daktronics
DAKT
$986M
| $2.82M | ﹤0.01% |
292,700
+91,400
| +45% | +$862K |
|
2065
Hingham Institution for Saving
HIFS
$680M
| $2.8M | ﹤0.01% |
15,400
+1,600
| +12% | +$283K |
|
|
HALL
2066
DELISTED
Hallmark Financial Services, Inc.
HALL
| $2.8M | ﹤0.01% |
24,866
+5,837
| +31% | +$626K |
|
2067
Vertex Pharmaceuticals
VRTX
$128B
| $2.8M | ﹤0.01% |
21,700
-18,417
| -46% | -$2.22M |
|
|
KAMN
2068
DELISTED
Kaman Corp
KAMN
| $2.79M | ﹤0.01% |
56,022
-153,900
| -73% | -$7.49M |
|
|
EVOL
2069
DELISTED
Evolving Systems, Inc.
EVOL
| $2.79M | ﹤0.01% |
541,499
+33,050
| +7% | +$168K |
|
2070
INNOVATE Corp
VATE
$109M
| $2.78M | ﹤0.01% |
47,283
+27,673
| +141% | +$1.59M |
|
2071
TransAlta
TAC
$4.05B
| $2.78M | ﹤0.01% |
434,000
+27,400
| +7% | +$152K |
|
2072
Allient
ALNT
$1.89B
| $2.77M | ﹤0.01% |
152,550
+25,950
| +20% | +$428K |
|
|
PCO
2073
DELISTED
Pendrell Corporation - Class A
PCO
| $2.76M | ﹤0.01% |
3,821
+1,534
| +67% | +$959K |
|
|
SEAC
2074
DELISTED
Seachange International Inc
SEAC
| $2.76M | ﹤0.01% |
51,881
+3,436
| +7% | +$174K |
|
|
XIFR
2075
XPLR Infrastructure LP
XIFR
$1.11B
| $2.76M | ﹤0.01% |
+74,500
| New | +$2.57M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.